Diamedica Therapeutics Inc., a phase II biopharma targeting acute ischemic stroke and chronic kidney disease, completed its micro-IPO, raising $16.4 million by offering 4.1 million shares at $4, the low end of its proposed range. Synthorx Inc. went bigger, hauling in $131 million by offering 11.9 million shares at $11, the midpoint of its proposed $10 to $12 range.